the Safety, Tolerability, and Pharmacokinetics Study of HEC113995

Exclusion Criteria

• •1\. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening.
• •2\. Subjects with history of digestive system,urinary system, liver,central nervous system, blood system, endocrine system,respiratory system,immune system,cardiovascular system,and/or malignant tumor or others medical conditions (such as history of mental illness, etc.) that are not suitable for clinical trial participation;Subjects with history of epilepsy, bipolar disorder/mania, high intraocular pressure, or acute angular-closure glaucoma.
• •3\. Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s) ,or anaphylaxis physique.
• •4\. Use of any prescription or non-prescription medications within 14 days prior to initial dosing,or Use of any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing.
• •5\. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
• •6\. Positive results from urine drug screen test.
• •7\. History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of \> 21 units/week), or positive results from alcohol breath test.
• •8\. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug.
• •9\. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
• •10\. Subjects who plan to receive or have had organ transplants.
• •11\. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential.
• •12\. Subjects who participated in another clinical trial within 3 months prior to initial dosing.
• •13\. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.